European Approval For Roxadustat Is Silver Lining For FibroGen

But Will Not Head Off Restructuring

 
• By Andrew McConaghie

The EU approval is good news for FibroGen and marketing partner Astellas, but was expected, and still leaves it pondering its future after FDA knock-back.

Amsterdam, March 2020. Entrance of the office from the European Medicines Agency (EMA) in Amsterdam
Based on guidance from the EMA (pictured), the EU approval is good news for FibroGen and its partner Astellas, but does not compensate for the drug's rejection in the US.

More from Blood and Clotting

More from Therapy Areas